Drug Profile
AZD 3043
Alternative Names: AZD3043; TD 4756; THRX 918661Latest Information Update: 03 Aug 2011
Price :
$50
*
At a glance
- Originator Theravance
- Developer AstraZeneca
- Class Anaesthetics; Esters; Hypnosedatives
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaesthesia
Most Recent Events
- 28 Jul 2011 Discontinued - Phase-I for Anaesthesia in Sweden (IV)
- 28 Jul 2011 Discontinued - Phase-I for Anaesthesia in United Kingdom (IV)
- 17 Dec 2009 AstraZeneca completes a second phase I trial in Anaesthesia in Sweden